{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:34:11Z","timestamp":1792020851102,"version":"4.4.0"},"reference-count":146,"publisher":"European Respiratory Society (ERS)","issue":"169","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2023,7,20]]},"published-print":{"date-parts":[[2023,9,30]]},"abstract":"<jats:p>Exacerbations of COPD are associated with worsening of the airflow obstruction, hospitalisation, reduced quality of life, disease progression and death. At least 70% of COPD exacerbations are infectious in origin, with respiratory viruses identified in approximately 30% of cases. Despite long-standing recommendations to vaccinate patients with COPD, vaccination rates remain suboptimal in this population.<\/jats:p><jats:p><jats:italic>Streptococcus pneumoniae<\/jats:italic>is one of the leading morbidity and mortality causes of lower respiratory tract infections. The Food and Drug Administration recently approved pneumococcal conjugate vaccines that showed strong immunogenicity against all 20 included serotypes. Influenza is the second most common virus linked to severe acute exacerbations of COPD. The variable vaccine efficacy across virus subtypes and the impaired immune response are significant drawbacks in the influenza vaccination strategy. High-dose and adjuvant vaccines are new approaches to tackle these problems. Respiratory syncytial virus is another virus known to cause acute exacerbations of COPD. The vaccine candidate RSVPreF3 is the first authorised for the prevention of RSV in adults \u226560\u2005years and might help to reduce acute exacerbations of COPD. The 2023 Global Initiative for Chronic Lung Disease report recommends zoster vaccination to protect against shingles for people with COPD over 50\u2005years.<\/jats:p>","DOI":"10.1183\/16000617.0034-2023","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T09:30:24Z","timestamp":1693992624000},"page":"230034","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":66,"title":["The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus"],"prefix":"10.1183","volume":"32","author":[{"given":"Susanne","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Joean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-7356","authenticated-orcid":false,"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2024102404142819000_32.169.230034.1","doi-asserted-by":"crossref","first-page":"31893","DOI":"10.1038\/srep31893","article-title":"Projecting the COPD population and costs in England and Scotland: 2011 to 2030","volume":"6","author":"McLean","year":"2016","journal-title":"Sci Rep"},{"key":"2024102404142819000_32.169.230034.2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4274\/balkanmedj.2016.1028","article-title":"Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease","volume":"34","author":"Aka Akt\u00fcrk","year":"2017","journal-title":"Balk Med J"},{"key":"2024102404142819000_32.169.230034.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2013.11.001"},{"key":"2024102404142819000_32.169.230034.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2024102404142819000_32.169.230034.5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12931-022-01947-5","article-title":"Antimicrobial therapies for prevention of recurrent acute exacerbations of COPD (AECOPD): beyond the guidelines","volume":"23","author":"Brennan","year":"2022","journal-title":"Respir Res"},{"key":"2024102404142819000_32.169.230034.6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu024"},{"key":"2024102404142819000_32.169.230034.7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23495"},{"key":"2024102404142819000_32.169.230034.8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209023"},{"key":"2024102404142819000_32.169.230034.9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/22221751.2021.1957402","article-title":"The impact of the SARS-CoV-2 pandemic on the prevalence of respiratory tract pathogens in patients with community-acquired pneumonia in Germany","volume":"10","author":"D\u00e4hne","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"2024102404142819000_32.169.230034.10","doi-asserted-by":"crossref","first-page":"00703-02022","DOI":"10.1183\/23120541.00703-2022","article-title":"Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021","volume":"9","author":"Ankert","year":"2023","journal-title":"ERJ Open Res"},{"key":"2024102404142819000_32.169.230034.11","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2015-0011"},{"key":"2024102404142819000_32.169.230034.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"2024102404142819000_32.169.230034.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184877"},{"key":"2024102404142819000_32.169.230034.14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2213-2600(22)00494-5","article-title":"GOLD COPD report: 2023 update","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024102404142819000_32.169.230034.15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis212"},{"key":"2024102404142819000_32.169.230034.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.019"},{"key":"2024102404142819000_32.169.230034.17","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.2.308-318.2003"},{"key":"2024102404142819000_32.169.230034.18","first-page":"CD001390","article-title":"Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease","volume":"2010","author":"Walters","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102404142819000_32.169.230034.19","doi-asserted-by":"publisher","DOI":"10.1038\/nri2494"},{"key":"2024102404142819000_32.169.230034.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"2024102404142819000_32.169.230034.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.11.026"},{"key":"2024102404142819000_32.169.230034.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.05.003"},{"key":"2024102404142819000_32.169.230034.23","doi-asserted-by":"crossref","first-page":"2168354","DOI":"10.1080\/20018525.2023.2168354","article-title":"Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis","volume":"10","author":"Sikj\u00e6r","year":"2023","journal-title":"Eur Clin Respir J"},{"key":"2024102404142819000_32.169.230034.24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales","volume":"6","author":"Djennad","year":"2018","journal-title":"EClinicalMedicine"},{"key":"2024102404142819000_32.169.230034.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ096"},{"key":"2024102404142819000_32.169.230034.26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/infdis\/jiab474","article-title":"Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study","volume":"225","author":"Heo","year":"2022","journal-title":"J Infect Dis"},{"key":"2024102404142819000_32.169.230034.27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.arbres.2022.12.015","article-title":"Pneumococcal vaccination in adults: what can we learn from observational studies that evaluated PCV13 and PPV23 effectiveness in the same population?","volume":"59","author":"Dunne","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"2024102404142819000_32.169.230034.28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.vaccine.2022.12.060","article-title":"Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-na\u00efve adults aged \u226565 years: comparison of booster effects based on intervals of 0.5 and 1.0\u2005year","volume":"41","author":"Azuma","year":"2023","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.29","doi-asserted-by":"crossref","first-page":"15948","DOI":"10.1038\/s41598-021-95129-w","article-title":"Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study","volume":"11","author":"Ignatova","year":"2021","journal-title":"Sci Rep"},{"key":"2024102404142819000_32.169.230034.30","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/j.vaccine.2022.06.024","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States","volume":"40","author":"Huang","year":"2022","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30052-5"},{"key":"2024102404142819000_32.169.230034.32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","article-title":"Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study","volume":"21","author":"Ouldali","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102404142819000_32.169.230034.33","first-page":"jiac376","article-title":"Nasopharyngeal carriage of pneumococcus in children in England up to ten years after PCV13 introduction: persistence of serotypes 3 and 19A and emergence of 7C","volume":"227","author":"Tiley","year":"2022","journal-title":"J Infect Dis"},{"key":"2024102404142819000_32.169.230034.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02432-2021"},{"key":"2024102404142819000_32.169.230034.35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab990"},{"key":"2024102404142819000_32.169.230034.36","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49\u2005years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.37","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565\u2005years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.38","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/13696998.2022.2152235","article-title":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23","volume":"25","author":"Olsen","year":"2022","journal-title":"J Med Econ"},{"key":"2024102404142819000_32.169.230034.39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","article-title":"Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease","volume":"22","author":"Mendes","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2024102404142819000_32.169.230034.40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024102404142819000_32.169.230034.41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/vaccines10020311","article-title":"Low adherence to pneumococcal vaccination in lung cancer patients in a tertiary care university hospital in southern Germany","volume":"10","author":"Mohr","year":"2022","journal-title":"Vaccines"},{"key":"2024102404142819000_32.169.230034.42","doi-asserted-by":"crossref","first-page":"106988","DOI":"10.1016\/j.rmed.2022.106988","article-title":"Are younger COPD patients adequately vaccinated for influenza and pneumococcus?","volume":"203","author":"Gogou","year":"2022","journal-title":"Respir Med"},{"key":"2024102404142819000_32.169.230034.43","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/21645515.2019.1613128","article-title":"Influenza and pneumonia vaccination rates in patients hospitalized with acute respiratory failure","volume":"15","author":"Candemir","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"2024102404142819000_32.169.230034.44","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/resp.14309","article-title":"Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations","volume":"27","author":"Li","year":"2022","journal-title":"Respirol Carlton Vic"},{"key":"2024102404142819000_32.169.230034.45","doi-asserted-by":"crossref","first-page":"2102840","DOI":"10.1080\/21645515.2022.2102840","article-title":"Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease","volume":"18","author":"Saiphoklang","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"2024102404142819000_32.169.230034.46","unstructured":"Centers for Disease Control and Prevention . People at higher risk of flu complications. Date last accessed: 9 August 2023. Date last updated: 6 September 2022. www.cdc.gov\/flu\/highrisk\/index.htm"},{"key":"2024102404142819000_32.169.230034.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33293-2"},{"key":"2024102404142819000_32.169.230034.48","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","article-title":"The disease burden of influenza beyond respiratory illness","volume":"39","author":"Macias","year":"2021","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.gheart.2014.08.004","article-title":"Global burden of influenza as a cause of cardiopulmonary morbidity and mortality","volume":"9","author":"Fischer","year":"2014","journal-title":"Glob Heart."},{"key":"2024102404142819000_32.169.230034.50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamacardio.2016.0433","article-title":"Seasonal influenza infections and cardiovascular disease mortality","volume":"1","author":"Nguyen","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024102404142819000_32.169.230034.51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/M20-1509","article-title":"Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study","volume":"173","author":"Chow","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024102404142819000_32.169.230034.52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057042"},{"key":"2024102404142819000_32.169.230034.53","unstructured":"European Centre for Disease Prevention and Control . Risk groups for severe influenza. Date last accessed: 9 August 2023. Date last updated: 9 March 2023. www.ecdc.europa.eu\/en\/seasonal-influenza\/prevention-and-control\/vaccines\/risk-groups"},{"key":"2024102404142819000_32.169.230034.54","unstructured":"World Health Organization . Influenza (seasonal). Date last updated: 12 January 2023. www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)"},{"key":"2024102404142819000_32.169.230034.55","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2147\/COPD.S306916","article-title":"Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease","volume":"16","author":"Jang","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102404142819000_32.169.230034.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.10.044"},{"key":"2024102404142819000_32.169.230034.57","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurjpc\/zwac152","article-title":"Cardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis","volume":"29","author":"Jaiswal","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2024102404142819000_32.169.230034.58","unstructured":"Organisation for Economic Co-operation and Development . Influenza vaccination rates. Date last accessed: 9 August 2023. Date last updated: 2022. https:\/\/data.oecd.org\/healthcare\/influenza-vaccination-rates.htm"},{"key":"2024102404142819000_32.169.230034.59","unstructured":"European Centre for Disease Prevention and Control . Seasonal influenza. Date last accessed: 9 August 2023. Date last updated: 7 July 2023. www.ecdc.europa.eu\/en\/seasonal-influenza"},{"key":"2024102404142819000_32.169.230034.60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbres.2015.09.001","article-title":"Prevalence of influenza vaccination in chronic obstructive pulmonary disease patients and impact on the risk of severe exacerbations","volume":"52","author":"Garrastazu","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"2024102404142819000_32.169.230034.61","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1038\/s41598-022-08952-0","article-title":"Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases","volume":"12","author":"Mart\u00ednez-Baz","year":"2022","journal-title":"Sci Rep"},{"key":"2024102404142819000_32.169.230034.62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/infdis\/jiz419","article-title":"Influenza vaccine effectiveness in preventing hospitalizations in older patients with chronic obstructive pulmonary disease","volume":"221","author":"Gershon","year":"2020","journal-title":"J Infect Dis"},{"key":"2024102404142819000_32.169.230034.63","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2015.1043518"},{"key":"2024102404142819000_32.169.230034.64","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4161\/hv.24704","article-title":"Influenza vaccines in low and middle income countries: a systematic review of economic evaluations","volume":"9","author":"Ott","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"2024102404142819000_32.169.230034.65","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00129-8"},{"key":"2024102404142819000_32.169.230034.66","doi-asserted-by":"crossref","first-page":"e4229","DOI":"10.1093\/cid\/ciaa1916","article-title":"Adjuvanted influenza vaccine and influenza outbreaks in US nursing homes: results from a pragmatic cluster-randomized clinical trial","volume":"73","author":"Gravenstein","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102404142819000_32.169.230034.67","doi-asserted-by":"crossref","first-page":"e4237","DOI":"10.1093\/cid\/ciaa1233","article-title":"Cluster-randomized trial of adjuvanted versus nonadjuvanted trivalent influenza vaccine in 823 US nursing homes","volume":"73","author":"McConeghy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102404142819000_32.169.230034.68","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1016\/j.vaccine.2020.05.020","article-title":"Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population","volume":"38","author":"Paudel","year":"2020","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.69","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1016\/j.vaccine.2020.08.011","article-title":"Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015\u201316 to 2018\u201319","volume":"38","author":"Balasubramani","year":"2020","journal-title":"Vaccine"},{"key":"2024102404142819000_32.169.230034.70","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1471989"},{"key":"2024102404142819000_32.169.230034.71","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/vaccines10091387","article-title":"A comparative analysis of influenza-associated disease burden with different influenza vaccination strategies for the elderly population in South Korea","volume":"10","author":"Choi","year":"2022","journal-title":"Vaccines"},{"key":"2024102404142819000_32.169.230034.72","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/vaccines10091386","article-title":"The cost-effectiveness of vaccination of older adults with an mf59-adjuvanted quadrivalent influenza vaccine compared to other available quadrivalent vaccines in Germany","volume":"10","author":"Kohli","year":"2022","journal-title":"Vaccines"},{"key":"2024102404142819000_32.169.230034.73","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102404142819000_32.169.230034.74","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ijid.2022.07.048","article-title":"Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis","volume":"122","author":"Domnich","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2024102404142819000_32.169.230034.75","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0271"},{"key":"2024102404142819000_32.169.230034.76","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.amjmed.2021.05.008","article-title":"Population decline in COPD admissions during the COVID-19 pandemic associated with lower burden of community respiratory viral infections","volume":"134","author":"So","year":"2021","journal-title":"Am J Med"},{"key":"2024102404142819000_32.169.230034.77","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216526"},{"key":"2024102404142819000_32.169.230034.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2020.07.023"},{"key":"2024102404142819000_32.169.230034.79","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17476348.2022.2092099","article-title":"Vaccination and modern management of chronic obstructive pulmonary disease \u2013 a narrative review","volume":"16","author":"Joean","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"2024102404142819000_32.169.230034.80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255659"},{"key":"2024102404142819000_32.169.230034.81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.chest.2020.12.057","article-title":"Clinical consequences of COVID-19 lockdown in patients with COPD: results of a pre-post study in Spain","volume":"160","author":"Gonz\u00e1lez","year":"2021","journal-title":"Chest"},{"key":"2024102404142819000_32.169.230034.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00547-2020"},{"key":"2024102404142819000_32.169.230034.83","doi-asserted-by":"crossref","first-page":"100515","DOI":"10.1016\/j.eclinm.2020.100515","article-title":"SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: an analysis of Cleveland clinic's COVID-19 registry","volume":"26","author":"Attaway","year":"2020","journal-title":"eClinicalMedicine"},{"key":"2024102404142819000_32.169.230034.84","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/COPD.S318000","article-title":"Mortality from COVID-19 in patients with COPD: a US study in the N3C data enclave","volume":"16","author":"Meza","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102404142819000_32.169.230034.85","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04474-2020"},{"key":"2024102404142819000_32.169.230034.86","unstructured":"Centers for Disease Control and Prevention . Interim clinical considerations for use of COVID-19 vaccines in the United States. Date last accessed: 9 August 2023. Date last updated: 12 May 2023. www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html"},{"key":"2024102404142819000_32.169.230034.87","unstructured":"Robert Koch Institut . COVID-19-Impfempfehlung. Date last updated: 20 June 2023. www.rki.de\/SharedDocs\/FAQ\/COVID-Impfen\/FAQ_Liste_STIKO_Empfehlungen.html"},{"key":"2024102404142819000_32.169.230034.88","unstructured":"Centers for Disease Control and Prevention . COVID data tracker. Date last accessed: 9 August 2023. https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"2024102404142819000_32.169.230034.89","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/infdis\/jiab619","article-title":"Effectiveness of mRNA vaccines against COVID-19 hospitalization by age and chronic medical conditions burden among immunocompetent US adults, March\u2013August 2021","volume":"225","author":"Lewis","year":"2021","journal-title":"J Infect Dis"},{"key":"2024102404142819000_32.169.230034.90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2101765"},{"key":"2024102404142819000_32.169.230034.91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2024102404142819000_32.169.230034.92","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chest.2021.12.654","article-title":"Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions","volume":"161","author":"Liao","year":"2022","journal-title":"Chest"},{"key":"2024102404142819000_32.169.230034.93","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00497-2022"},{"key":"2024102404142819000_32.169.230034.94","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.1.70-80.2005"},{"key":"2024102404142819000_32.169.230034.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674"},{"key":"2024102404142819000_32.169.230034.96","unstructured":"Centers for Disease Control and Prevention . Shingles burden and trends. Date last accessed: 9 August 2023. Date last updated: 10 May 2023. www.cdc.gov\/shingles\/surveillance.html"},{"key":"2024102404142819000_32.169.230034.97","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341"},{"key":"2024102404142819000_32.169.230034.98","unstructured":"European Medicines Agency . Shingrix. Date last updated: 19 December 2022. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix."},{"key":"2024102404142819000_32.169.230034.99","unstructured":"Centers for Disease Control and Prevention . Vaccination. Date last updated: 24 January 2022. www.cdc.gov\/shingles\/vaccination.html"},{"key":"2024102404142819000_32.169.230034.100","unstructured":"Centers for Disease Control and Prevention . What everyone should know about Zostavax. Date last accessed: 9 August 2023. Date last updated: 5 October 2020. www.cdc.gov\/vaccines\/vpd\/shingles\/public\/zostavax\/index.html"},{"key":"2024102404142819000_32.169.230034.101","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/ofid\/ofx163.1033","article-title":"Performance of zoster vaccine live (Zostavax): a systematic review of 12\u2005years of experimental and observational evidence","volume":"4","author":"Dooling","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2024102404142819000_32.169.230034.102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"2024102404142819000_32.169.230034.103","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9053"},{"key":"2024102404142819000_32.169.230034.104","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30163-X"},{"key":"2024102404142819000_32.169.230034.105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/crj.13554","article-title":"Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective United States claims database analysis","volume":"16","author":"Thompson-Leduc","year":"2022","journal-title":"Clin Respir J"},{"key":"2024102404142819000_32.169.230034.106","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101137"},{"key":"2024102404142819000_32.169.230034.107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12879-018-3121-x","article-title":"Risk and impact of herpes zoster among COPD patients: a population-based study, 2009\u20132014","volume":"18","author":"Mu\u00f1oz-Quiles","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2024102404142819000_32.169.230034.108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181565"},{"key":"2024102404142819000_32.169.230034.109","doi-asserted-by":"crossref","first-page":"ofad137","DOI":"10.1093\/ofid\/ofad137","article-title":"Increased myocardial infarction risk following herpes zoster infection","volume":"10","author":"Parameswaran","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024102404142819000_32.169.230034.110","doi-asserted-by":"crossref","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatol"},{"key":"2024102404142819000_32.169.230034.111","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.04.014","article-title":"Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases","volume":"12","author":"Rodr\u00edguez-Jim\u00e9nez","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2024102404142819000_32.169.230034.112","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2021.11.025","article-title":"Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study","volume":"87","author":"Birabaharan","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024102404142819000_32.169.230034.113","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-013-8368-9"},{"key":"2024102404142819000_32.169.230034.114","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5021"},{"key":"2024102404142819000_32.169.230034.115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"2024102404142819000_32.169.230034.116","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J Infect Dis"},{"key":"2024102404142819000_32.169.230034.117","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024102404142819000_32.169.230034.118","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00580-12"},{"key":"2024102404142819000_32.169.230034.119","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00383-6"},{"key":"2024102404142819000_32.169.230034.120","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines9060624","article-title":"Considerations for a respiratory syncytial virus vaccine targeting an elderly population","volume":"9","author":"Stephens","year":"2021","journal-title":"Vaccines"},{"key":"2024102404142819000_32.169.230034.121","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120955"},{"key":"2024102404142819000_32.169.230034.122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442507"},{"key":"2024102404142819000_32.169.230034.123","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30292-5"},{"key":"2024102404142819000_32.169.230034.124","doi-asserted-by":"crossref","unstructured":"Jordan E , Kabir G , Schultz S , et al. Reduced respiratory syncytial virus load, symptoms, and infections: a human challenge trial of MVA-BN-RSV vaccine. J Infect Dis 2023; in press [https:\/\/doi.org\/10.1093\/infdis\/jiad108]","DOI":"10.1093\/infdis\/jiad108"},{"key":"2024102404142819000_32.169.230034.125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207566"},{"key":"2024102404142819000_32.169.230034.126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"key":"2024102404142819000_32.169.230034.127","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa2116154","article-title":"Vaccine efficacy in adults in a respiratory syncytial virus challenge study","volume":"386","author":"Schmoele-Thoma","year":"2022","journal-title":"N Engl J Med"},{"key":"2024102404142819000_32.169.230034.128","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/irv.13050","article-title":"Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease","volume":"16","author":"Mulpuru","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"2024102404142819000_32.169.230034.129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.chest.2018.09.027","article-title":"Clinically diagnosing pertussis-associated cough in adults and children","volume":"155","author":"Moore","year":"2019","journal-title":"Chest"},{"key":"2024102404142819000_32.169.230034.130","first-page":"1283","article-title":"Pertussis\u2013United States, 2001\u20132003","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024102404142819000_32.169.230034.131","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/21645515.2020.1738168","article-title":"Pertussis in high-risk groups: an overview of the past quarter-century","volume":"16","author":"Jenkins","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"2024102404142819000_32.169.230034.132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines11010001","article-title":"Evaluation of whole-cell and acellular pertussis vaccines in the context of long-term herd immunity","volume":"11","author":"Szwejser-Zawislak","year":"2022","journal-title":"Vaccines"},{"key":"2024102404142819000_32.169.230034.133","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1748"},{"key":"2024102404142819000_32.169.230034.134","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/15412555.2021.1899155","article-title":"Burden of pertussis in COPD: a retrospective database study in England","volume":"18","author":"Aris","year":"2021","journal-title":"COPD"},{"key":"2024102404142819000_32.169.230034.135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40121-022-00747-0","article-title":"Risk factors of pertussis among older adults in South Korea: a nationwide health data-based case-control study","volume":"12","author":"Kim","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2024102404142819000_32.169.230034.136","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210408"},{"key":"2024102404142819000_32.169.230034.137","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(21)00502-6","article-title":"Non-typeable Haemophilus influenzae\u2013Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial","volume":"10","author":"Andreas","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102404142819000_32.169.230034.138","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s15010-021-01605-w","article-title":"Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade","volume":"49","author":"Braeken","year":"2021","journal-title":"Infection"},{"key":"2024102404142819000_32.169.230034.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.02.010"},{"key":"2024102404142819000_32.169.230034.140","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"2024102404142819000_32.169.230034.141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315727"},{"key":"2024102404142819000_32.169.230034.142","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.arr.2021.101337","article-title":"Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"68","author":"Bao","year":"2021","journal-title":"Ageing Res Rev"},{"key":"2024102404142819000_32.169.230034.143","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/vaccines11040753","article-title":"Cost-effectiveness of vaccination of older adults with an MF59\u00ae-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in Denmark, Norway, and Sweden","volume":"11","author":"Jacob","year":"2023","journal-title":"Vaccines"},{"key":"2024102404142819000_32.169.230034.144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2024102404142819000_32.169.230034.145","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00037410"},{"key":"2024102404142819000_32.169.230034.146","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/infdis\/jiab128","article-title":"Prevention of coronavirus disease 2019 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and severe acute respiratory syndrome coronavirus 2 in the respiratory tract","volume":"225","author":"Lewnard","year":"2022","journal-title":"J Infect Dis"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0034-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:06:22Z","timestamp":1740373582000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0034-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":146,"journal-issue":{"issue":"169","published-online":{"date-parts":[[2023,9,6]]},"published-print":{"date-parts":[[2023,9,30]]}},"alternative-id":["10.1183\/16000617.0034-2023"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0034-2023","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}